Clinical Trial

Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06 -> 2026-12 2026-08-05
minor Completion pushed: 2026-06 -> 2026-12 2026-08-05
Trial Details
NCT Number NCT07187479
Lead Sponsor Well Cell Global
Conditions Chronic Kidney Disease (Stages 4 and 5), Kidney Disease, Type 2 Diabetes
Enrollment 120 participants
Start Date 2025-10-14
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-04